Berenberg Bank Boosts Hikma Pharmaceuticals (LON:HIK) Price Target to GBX 2,560

Hikma Pharmaceuticals (LON:HIK) had its price objective hoisted by investment analysts at Berenberg Bank from GBX 2,400 ($29.81) to GBX 2,560 ($31.79) in a research note issued to investors on Wednesday, MarketBeat reports. The brokerage currently has a “buy” rating on the stock. Berenberg Bank’s price objective would suggest a potential upside of 12.28% from the stock’s current price.

Hikma Pharmaceuticals Stock Performance

LON:HIK opened at GBX 2,280 ($28.32) on Wednesday. The company has a market capitalization of £5.06 billion, a price-to-earnings ratio of 3,507.69, a PEG ratio of 2.38 and a beta of 0.41. The business has a 50 day moving average of GBX 2,001.97 and a 200 day moving average of GBX 1,947.80. The company has a debt-to-equity ratio of 55.48, a current ratio of 1.66 and a quick ratio of 1.27. Hikma Pharmaceuticals has a 1-year low of GBX 1,750 ($21.73) and a 1-year high of GBX 2,290 ($28.44).

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.